Microbiological Etiology in Patients with IE Undergoing Surgery and for Patients with Medical Treatment Only: A Nationwide Study from 2010 to 2020

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 2,62 MB, PDF-dokument

first_pagesettingsOrder Article Reprints
Open AccessArticle
Microbiological Etiology in Patients with IE Undergoing Surgery and for Patients with Medical Treatment Only: A Nationwide Study from 2010 to 2020
by Peter Laursen Graversen 1,*ORCID,Lauge Østergaard 1,Marianne Voldstedlund 2ORCID,Malthe Faurschou Wandall-Holm 3ORCID,Morten Holdgaard Smerup 4,Lars Køber 1,5 andEmil Loldrup Fosbøl 1,5
1
Department of Cardiology, Copenhagen University Hospital—Rigshospitalet, 2100 Copenhagen, Denmark
2
Department of Data Integration and Analysis, Statens Serum Institut, 2300 Copenhagen, Denmark
3
Danish Multiple Sclerosis Registry, Department of Neurology, University of Copenhagen—Rigshospitalet, 2600 Glostrup, Denmark
4
Department of Cardiothoracic Surgery, Copenhagen University Hospital—Rigshospitalet, 2100 Copenhagen, Denmark
5
Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark
*
Author to whom correspondence should be addressed.
Microorganisms 2023, 11(10), 2403; https://doi.org/10.3390/microorganisms11102403
Original submission received: 10 July 2023 / Revised: 21 September 2023 / Accepted: 23 September 2023 / Published: 26 September 2023
(This article belongs to the Special Issue The Infective Endocarditis)
Downloadkeyboard_arrow_down Browse Figures Review Reports Versions Notes
Abstract
Microbiological etiology has been associated with surgery for infective endocarditis (IE) during admission, especially Staphylococcus aureus. We aimed to compare patient characteristics, microbiological characteristics, and outcomes by treatment choice (surgery or not). We identified patients with first-time IE between 2010 and 2020 and examined the microbiological etiology of IE according to treatment choice. To identify factors associated with surgery during initial admission, we used the Aalen–Johansen estimator and an adjusted cause-specific Cox model. One-year mortality stratified by microbiological etiology and treatment choice was assessed using unadjusted Kaplan–Meier estimates and an adjusted Cox proportional hazard model. A total of 6255 patients were included, of which 1276 (20.4%) underwent surgery during admission. Patients who underwent surgery were younger (65 vs. 74 years) and less frequently had cerebrovascular disease, cardiovascular disease, diabetes, and chronic kidney disease. Patients with Staphylococcus aureus IE were less likely to undergo surgery during admission (13.6%) compared to all other microbiological etiologies. One-year mortality according to microbiological etiology in patients who underwent surgery was 7.0%, 5.3%, 5.5%, 9.6%, 13.2, and 11.2% compared with 24.2%, 19.1%, 27,6%, 25.2%, 21%, and 16.9% in patients who received medical therapy for Staphylococcus aureus, Streptococcus spp., Enterococcus spp., coagulase-negative Staphylococci, “other microbiological etiologies”, and blood culture-negative infective endocarditis, respectively. Patients with IE who underwent surgery differed in terms of microbiology, more often having Streptococci than those who received medical therapy. Contrary to expectations, Staphylococcus aureus was more common among patients who received medical therapy only.
Keywords: microorganism; infective endocarditis; surgery; microbiological etiology; microbiological characteristics
OriginalsprogEngelsk
Artikelnummer2403
TidsskriftMicroorganisms
Vol/bind11
Udgave nummer10
Antal sider15
ISSN2076-2607
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
This work was supported by the Novo Nordisk Foundation (20OC0060362) for the coverage of the salary to PLG.

Funding Information:
Peter L. Graversen: Independent research grant provided by the Novo Nordisk Foundation for research in valvular heart disease. However, the foundation did not have any influence on the study design, data acquisition, data analysis, or preparation of the manuscript, neither did it have any influence on the publication process. Lauge Østergaard: independent research grant from the Novo Nordisk Foundation for the study of mitral valve regurgitation. Marianne Voldstedlund: speaker’s honorarium from MyLab Oy, Tampere, Finland, unrelated to this manuscript. Malthe Faurschou Wandall-Holm: served on scientific advisory board for Sanofi and received speaker’s honorarium from Novartis and Sanofi, unrelated to this manuscript. Morten Holdgaard Smerup: The author declares no conflict of interest. Lars Køber: speaker’s honorarium from Nova, Novartis, AstraZeneca, Bayer, and Boehringer, unrelated to this manuscript. Emil Loldrup Fosbøl: an independent research grant provided by the Novo Nordisk Foundation for research in valvular heart disease.

Publisher Copyright:
© 2023 by the authors.

ID: 375795130